micro2MACRO is a EU-Funded project developing a bioprinting platform for the rapid, reliable, controlled and quantifiable patterning of cellular aggregates and microtissues into macroscale regenerative grafts with programmable architectures.
The main goal of m2M is to develop a new bioprinting platform capable of spatially patterning numerous cellular aggregates or microtissues into scaled-up, personalised durable load-bearing grafts and guiding their (re)modelling into fully functional tissues in vivo within damaged or diseased environments. This will be achieved using a converged bioprinting approach capable of rapidly depositing cells and microtissues into guiding scaffold structures with high spatial resolution in a rapid, reliable, reproducible and quantifiable manner. These guiding structures will then function to direction the fusion and remodelling of cellular aggregates and microtissues into structurally organised tissues in vitro and in vivo, as well as providing medium-term (3-5 years) mechanical support to the regenerating tissue.
_____
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
Company Details
- Address
- The Challenge Of Nutrient Delivery In Cell Dense Bioprinted Tissues
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.m2mproject.eu
- Keywords
- ReLive Biotechnologies Limited.
M2m Questions
M2M's website is http://www.m2mproject.eu
M2M's LinkedIn profile is https://www.linkedin.com/company/m2mproject
M2M's industry is
Biotechnology Research
M2M's categories are Biotechnology Research
